Weigh In on Global Patent Application Forms
Published Date: 11/21/2025
Notice
Summary
The U.S. Patent and Trademark Office is asking for your thoughts on renewing a form related to the Patent Cooperation Treaty, which helps inventors apply for patents internationally. This update won’t cost you extra money but aims to keep paperwork simple and clear. You’ve got 30 days from November 21, 2025, to share your comments and help shape the process!
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
PCT Form Renewal Keeps Filing Requirements
If you file international patent applications under the Patent Cooperation Treaty, the USPTO is renewing the information collection (OMB Control Number 0651-0021). The renewal covers private-sector filers with an estimated 412,493 respondents and responses, takes between 0.25 and 4 hours per response, totals 343,739 annual burden hours, and carries an estimated $452,878,858 in annual non-hourly costs. Responding is required to obtain or retain patent-processing benefits under the treaty.
Mailing Cost Increase for PCT Submissions
If you mail PCT submissions, the postage estimate used by the USPTO rose from $10.40 to $11.20 for the Priority Mail legal flat rate envelope. That change increased the estimated postage costs from $42,900 to $46,200 and added $3,300 to the total annual non-hourly cost burden.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14939, Grant of Interim Extension of the Term of U.S. Patent No. 8,877,798; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means their patent, which was set to expire on July 25, 2026, now lasts until July 25, 2027. This extension helps Otsuka keep exclusive rights to their drug a bit longer while waiting for final FDA approval.
2026-14941, Grant of Interim Extension of the Term of U.S. Patent No. 8,461,196; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means they keep exclusive rights to the drug until July 25, 2027, giving them more time to sell it without competition. This extension helps the company protect their investment while the drug gets final approval.
2026-14793, Requirement To Identify All Real Parties in Interest to a Third Party Request for an Ex Parte Reexamination
The USPTO wants anyone asking for a third-party ex parte reexamination to clearly say who’s really behind the request. This helps stop sneaky tricks and keeps the process honest. If you’re involved, get ready to share this info confidentially by August 21, 2026, or risk delays or issues.
2026-14389, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Response to Office Action and Voluntary Amendment Forms
The USPTO is asking for public feedback on updating forms used to respond to trademark office actions and make voluntary changes. This affects anyone applying for or managing trademarks and could streamline the process without extra costs. Comments are open until September 15, 2026, so don’t miss your chance to weigh in!
2026-14388, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Admission to Practice and Roster of Registered Patent Attorneys and Agents Admitted to Practice Before the United States Patent and Trademark Office
The USPTO is asking for public feedback on its paperwork rules for patent attorneys and agents who want to practice before the office. This helps keep the process smooth and fair without making people fill out too many forms. If you have thoughts, send them in by August 17, 2026—no fees or big changes are happening right now, just a review.
2026-14239, Electronic Filing Systems for Filings Pursuant to the Protocol Relating to the Madrid Agreement Concerning the International Registration of Marks
Starting July 31, 2026, U.S. trademark applicants can use the new Madrid e-Filing system to submit international trademark applications and fix issues faster. This system, run by WIPO and approved by the USPTO, makes filing smoother and lets the USPTO communicate directly with applicants to help correct problems. If you file trademarks internationally, get ready for a quicker, easier process—no extra fees announced yet!
Previous / Next Documents
Previous: 2025-20514, Thermoformed Molded Fiber Products From China and Vietnam; Revised Schedule for the Subject Proceeding
The U.S. International Trade Commission is updating the timeline for reviewing thermoformed molded fiber products from China and Vietnam. Deadlines for filing briefs and comments have shifted to late November and early December 2025 due to a government shutdown delay. This affects businesses involved in importing or competing with these products and signals when final decisions and possible trade actions will happen.
Next: 2025-20516, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Legal Processes
The USPTO is asking for your thoughts on renewing a form they use to handle legal matters involving their employees. This update won’t cost you money but helps keep paperwork simple and fair. If you want to share your opinion, make sure to do it by December 22, 2025!